5:11 PM
 | 
Aug 08, 2008
 |  BC Extra  |  Company News

Multaq gets Priority Review

FDA granted Priority Review to an NDA from sanofi-aventis (Euronext:SAN; NYSE:SNY) for Multaq...

Read the full 54 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >